Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.

Children with Down syndrome are up to 150 times more likely to develop acute myeloid leukemia before age 5 and yet very ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.

Sanofi said that Sarclisa, its treatment for plasma cell cancer, was recommended for EU approval by the European Medicines Agency. The agency's Committee for Medicinal Products for Human Use ...

GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...

Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.

The Fresh Market’s most recent store opening in the Chicago neighborhood of Lincoln Park took the place of a Dom’s Kitchen ...

Neutrophil-to-lymphocyte ratio (NLR) is a significant prognostic indicator in myeloproliferative neoplasms, correlating with ...

However, our opinions are our own. See how we rate banking products to write unbiased product reviews. We check rates from many top nationwide financial institutions each day to help you find the ...